INmune Bio initiated with a Buy at Lucid Capital

Lucid Capital initiated coverage of INmune Bio (INMB) with a Buy rating and $25 price target INmune is one of the few companies in mid- to late-stage development for Alzheimer’s disease, the analyst tells investors in a research note. The firm expects mid-stage Alzheimer’s trial data in June and sees blockbuster potential for the company’s XPro.